Preview

August 2019

In the next issue of Pharma Technology Focus, we examine how the industry is responding to the growing threat of drug resistant tuberculosis, look back at key milestones in the decades long fight to prevent and treat HIV, and, after allegations that Teva orchestrated a sweeping scheme to inflate prices, we investigate what is going on with the company.


Also, we find out more about the dangers of unlicensed stem cell clinics, speak to the team behind research into the way that cancer cells communicate, and profile Verona’s ensifentrine to understand its potential as a life-changing solution for COPD patients.


Plus, we talk with Hedley Rees, author of the new book Taming the Big Pharma Monster about his experience in the UK pharma sector and how the industry could be modernised, and examine a UK initiative to create a ‘pay as you go’ database of AI programs for drug discovery firms.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor | Daniel Garrun

Writers | Allie Nawrat, Abi Millar, Chloe Kent
Magazine Designer | Marzia Del Gaone

Graphic Designers | Kate Cuntapay, Anett Arc, Sara Basto, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact our publishing assistant: Sophie Hoare

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Pharma Technology Focus is a product of Net Resources International. Copyright 2019 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | The deep dive for new drugsGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: Hapa Company InsightGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Owen MumfordGo to article: The pharma industry briefingGo to article: Capsugel Company InsightGo to article: Swiss WorldCargoGo to article: In the age of AMR, does a nationalised drug company make sense? The case for and againstGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Underwater forests and the search for natures’ next drug treasure troveGo to article: Barc Lab Go to article: BEAGo to article: Developing drugs for NASH: the race to market Go to article: SmartCAE Company InsightGo to article: SmartCAEGo to article: Zulresso: the world’s first post-partum depression drugGo to article: EcocoolGo to article: Moehs Iberica SLGo to article: Predicting drug flops with AIGo to article: Abiogen PharmaGo to article: LaudaGo to article: Proteomics and the promise of ‘enriching’ clinical trials Go to article: Lubrizol Life SciencesGo to article: SkycellGo to article: EventsGo to article: TemptimeGo to article: Next issueGo to article: Pfanstiehl Company InsightGo to article: Pfanstiehl